All Releases |
|---|
 |
XOMA Receives NASDAQ Determination Letter
Nov 19, 2009
|
9.0 KB
|
| |
BERKELEY, Calif., Nov 19, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that it received a letter from the staff of The NASDAQ Stock Market LLC on November 13, 2009 indicating that the NASDAQ staff has concluded that XOMA's previously-announced...
|
|
|
XOMA Appoints Jim Neal Vice President of Business Development
Nov 17, 2009
|
11.0 KB
|
| |
BERKELEY, Calif., Nov 17, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that James R. Neal has joined the company as Vice President, Business Development. Mr. Neal will oversee XOMA's business development strategy and lead the team to exe...
|
|
|
XOMA 052 Selected as a Top Ten Project to Watch
Nov 12, 2009
|
11.0 KB
|
| |
BERKELEY, Calif., Nov 12, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced its anti-inflammatory antibody to interleukin-1 beta (IL-1 beta), XOMA 052, has been selected as a Top Ten Cardiovascular/metabolic Project to Watch for partnering opportuni...
|
|
|
XOMA Announces Presentation at Lazard Healthcare Conference on November 18
Nov 11, 2009
|
10.5 KB
|
| |
BERKELEY, Calif., Nov 11, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Fred Kurland, Vice President and Chief Financial Officer of XOMA, is scheduled to present at the 6th annual Lazard Healthcare Conference on Wednesday, November 18, at 1...
|
|
|
XOMA Reports 2009 Third Quarter Financial Results
Nov 9, 2009
|
26.7 KB
|
| |
BERKELEY, Calif., Nov 9, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the third quarter and nine months ended September 30, 2009 and provided a general business update. XOMA has made significant progress in 2009...
|
|
|
XOMA Expands Development Strategy for XOMA 052 to Include Cardiovascular Diseases
Nov 6, 2009
|
14.6 KB
|
| |
BERKELEY, Calif., Nov 6, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the expansion of its development strategy for its XOMA 052 antibody to interleukin-1 beta (IL-1 beta) to include effects on cholesterol lowering, reducing plaque deposits an...
|
|
|
Phase 2 Trial of XOMA 052 to be Initiated in Type 1 Diabetes Patients
Nov 4, 2009
|
14.4 KB
|
| |
BERKELEY, Calif., Nov 4, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced plans to initiate an investigator sponsored Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. The trial ...
|
|
|
XOMA Granted First European Patent Covering XOMA 052
Nov 4, 2009
|
10.4 KB
|
| |
BERKELEY, Calif., Nov 4, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the grant of its first European Patent related to the XOMA 052 program. Granted by the European Patent Office, the patent covers XOMA's interleukin-1 beta (IL-1 beta) ...
|
|
|
XOMA to Announce Third Quarter 2009 Financial Results and Host Conference Call on November 9
Nov 3, 2009
|
10.7 KB
|
| |
BERKELEY, Calif., Nov 3, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that the company will host a conference call and webcast on Monday, November 9 at 9:00 a.m. Eastern time to discuss third quarter 2009 financial results and provide a general...
|
|
|
XOMA Signs Antibody Discovery Collaboration With Kaketsuken
Nov 3, 2009
|
10.9 KB
|
| |
BERKELEY, Calif., Nov 3, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA) and Kaketsuken have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new XOMA antibody phage display library, and a suite of integrated information and data management systems. ...
|
|
|
XOMA Presents First XOMA 052 Cardiovascular Disease Animal Model Results
Oct 20, 2009
|
12.3 KB
|
| |
BERKELEY, Calif., Oct 20, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation today of peer-reviewed results with XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), at two international conferences.
Preclinical results wit...
|
|
|
XOMA Appoints Susan Kramer, Dr. P.H. Vice President of Project and Alliance Management
Oct 14, 2009
|
10.6 KB
|
| |
BERKELEY, Calif., Oct 14, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA, Ltd (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced today the appointment of Susan Kramer, Dr. P.H., to the position of Vice President, Project and Alliance Management. A seasoned biopharmaceutical executive with 25 years of ...
|
|
|
XOMA Announces Initiation of Its Phase 2 Clinical Program for XOMA 052 in Type 2 Diabetes and Cardiovascular Disease
Oct 1, 2009
|
12.9 KB
|
| |
BERKELEY, Calif., Oct 1, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA) today announced plans for the Phase 2 clinical development of its anti-inflammatory drug candidate to interleukin-1 beta (IL-1 beta), XOMA 052, designed for the treatment of the inflammatory cause of cardiovascular, diabetes, autoimmune and other diseas...
|
|
|
XOMA Announces $13.9 Million Financing
Sep 30, 2009
|
9.2 KB
|
| |
BERKELEY, Calif., Sep 30, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA) today announced the sale of 18 million of its common shares to Azimuth Opportunity Ltd. for gross proceeds of $13.9 million, or approximately $0.77 per share, under its existing committed equity financing facility with Azimuth. The Company intends to u...
|
|
|
XOMA Presents Results Demonstrating Novel Mechanism of Action for XOMA 052 in Regulating IL-1 Beta Levels
Sep 30, 2009
|
11.7 KB
|
| |
VIENNA, Austria, Sep 30, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced new data demonstrating the unique regulatory mechanism of action of XOMA 052, a potent antibody drug candidate that inhibits the inflammatory cytokine interleukin-1 beta (IL...
|
|
|
XOMA Completes Full Repayment of Goldman Sachs Loan
Sep 24, 2009
|
11.1 KB
|
| |
BERKELEY, Calif., Sep 24, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA) today announced that it has fully repaid its loan from Goldman Sachs Specialty Holdings, Inc. Repayment of the loan discharged all of XOMA's obligations to the lenders. The repayment resolves the uncertainty about the loan that arose from the sudden an...
|
|
|
XOMA to Develop Therapeutic Antibody for H1N1 and H5N1 Influenza Viruses Under $2.2 Million U.S. Government Program Managed by SRI International
Sep 23, 2009
|
13.1 KB
|
| |
BERKELEY, Calif., Sep 23, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA) expanded its biodefense programs to include the development of a novel antibody that has been shown by Dana-Farber Cancer Institute and Harvard Medical School researchers to neutralize group 1 influenza A viruses, including the H1N1 and the H5N1 strain...
|
|
|
XOMA Receives Anticipated Deficiency Notice From NASDAQ
Sep 21, 2009
|
9.1 KB
|
| |
BERKELEY, Calif., Sep 21, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA) announced today that it has received notice from the NASDAQ Stock Market that for the 30 consecutive business days preceding September 15, 2009 the bid price of XOMA's common shares closed below the minimum $1.00 per share requirement under Marketplace...
|
|
|
XOMA Announces Plan to Fully Repay Goldman Sachs Loan
Sep 14, 2009
|
13.5 KB
|
| |
Sep 14, 2009 (GlobeNewswire via COMTEX News Network) --
Genentech Agrees to Buy Back its LUCENTIS Royalty Obligation
Company to Host Conference Call and Webcast at 8:30 am ET Today
BERKELEY, Calif., Sept. 14, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced a plan to fully repay its loan with Goldman Sac...
|
|
|
XOMA Announces $6 Million Antibody Discovery Collaboration With Arana Therapeutics
Sep 9, 2009
|
10.8 KB
|
| |
BERKELEY, Calif., Sep 9, 2009 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA) and Arana Therapeutics Limited, a wholly-owned subsidiary of Cephalon, Inc. (Nasdaq:CEPH) have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new antibody phage display librar...
|
|
|
$0.05
